ArticleBMC gastroenterology2025
Features on contrast-enhanced computed tomography for predicting recurrent esophageal variceal bleeding in patients with hepatocellular carcinoma.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEsophageal varices (EV) bleeding in patients with hepatocellular carcinoma (HCC) and liver cirrhosis is a life-threatening complication. We investigated whether features on multi-detector computed tomography (MDCT) could predict recurrent EV hemorrhage. MATERIALS AND
methodsIn this cross-sectional study, we retrospectively reviewed 72 patients with HCC and liver cirrhosis who received endoscopic therapy for EV bleeding between 2017 and 2022 at a single institution. Patients with both available contrast-enhanced CT scans taken before the bleeding episode within 6 months and upcoming 6-month follow-up medical records were included. We measured the diameter of the bulging submucosal EV on contrast-enhanced CT, presence of portal vein thrombosis (PVT), and patent umbilical vein (PUV). Demographic information, HCC staging, cirrhosis status as well as laboratory data were collected. The occurrence of recurrent EV bleeding requiring endoscopic therapy was investigated as the outcome.
resultsThe size of submucosal EVs larger than 9.5 mm was identified as the independent risk factor for recurrent EV bleeding in the next 6 months (the area under a receiver operating characteristic curve, AUROC: 0.816, P < 0.001) with 81.1% sensitivity and 80.0% specificity. The positive predictive value was 81.1%, indicating that high-risk EVs were 1.8 times more likely to bleed within the next six months.
conclusionCT scans exhibit excellent performance in predicting recurrent bleeding over the following 6 months. Aggressive endoscopic ligation or medical treatment for these patients with large EVs may improve survival and quality of life.
trial registrationThis study was retrospectively registered by the local Institutional Review Board of our hospital (approval No. 202400668B0).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.